330 results on '"Soo, R A"'
Search Results
2. Maternal histone methyltransferases antagonistically regulate monoallelic expression inC. elegans
3. Study on Reticent Students in the ESL Classrooms
4. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
5. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
6. EP17.04-03 Lung Cancer Care in Singapore: A review of the Healthcare Registry, 2013-2020
7. P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
8. EP06.03-10 HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics
9. Reticent Students in the ESL Classrooms
10. A toolkit for DNA assembly, genome engineering and multicolor imaging for C. elegans
11. A toolkit for DNA assembly, genome engineering and multicolor imaging for C. elegans
12. PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
13. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
14. LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
15. 405P Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
16. EP08.02-109 A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-Small Cell Lung Cancer
17. EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
18. Abstract 868: Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization
19. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
20. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
21. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
22. MA12.03 A Thoracic Cancers International COVID 19 Collaboration Survey on Patients’ Perceptions of COVID-19 (Teravolt-Paper)
23. P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
24. P28.01 Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
25. OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers
26. P48.06 A Network Meta-Analysis (MA) of First-Line Lung Cancer Treatment With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
27. 1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
28. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
29. 1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials
30. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
31. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer
32. Abstract 868: Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization
33. Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies?
34. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
35. Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients
36. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
37. 40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies
38. OA05.03 Real-World Global Data on Targeting Epidermal Growth Factor Receptor in Stage III Non-Small Cell Lung Cancer: The Results of the KINDLE Study
39. P84.09 Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC
40. Stability analysis for large scale time delay systems via the matrix Lyapunov function.
41. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
42. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
43. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
44. 1600P Low dose pembrolizumab is effective in the treatment of advanced non-small cell lung cancer (NSCLC) with reduced cost
45. 1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
46. Near-future ocean acidification causes differences in microbial associations within diverse coral reef taxa
47. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory’s analysis of 670 cases
48. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
49. Survie globale des patients atteints de CBNPC EGFRm+ recevant la séquence de traitement afatinib suivi d’osimertinib : analyse actualisée de l’étude GioTag
50. Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIS): Analysis of US insurance claims databases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.